Ensure Access to Orphan Drug Therapies through Collaborative Efforts with Government, Researchers and Patient Groups
In 2012, CBI is proud to present its 7th Annual Rare Disease and Orphan Drug Leadership Congress at a critical time for this community. Advocates of the 5,800 rare diseases that have no commercialized treatments are petitioning Congress to update the Orphan Drug Act of 1983. There is needed flexibility within clinical trial design to support smaller populations. Plus, there is continued pressure on payers to reimburse these treatments.
- Important Topics in 2012 Include:
- Proposed ULTRA Bill
- FDA/EMA Initiatives
- Pricing / Reimbursement Issues
- Partnerships with Patient Advocacy Groups
- Social Media
This conference is tri-located with CBI’s 3rd Annual Product Launch and Market Access Congress and CBI’s 5th Annual Congress on Expanded Access Programs for Investigational or Pre-Launch Drugs.
This conference is a part of CBI’s 3-Day Access World.
Access World brings together the delegations of the annual Congresses on Rare Disease, Access Programs for Investigational and Pre-Launch Drugs, and Product Launch and Market Access.
To take full advantage of Access World, register for one of the annual 2-day congresses and choose which program’s additional day of content you’d like to attend at the special Access World rate.
Program